ATE233084T1 - Pharmazeutische aerosolformulierung - Google Patents

Pharmazeutische aerosolformulierung

Info

Publication number: ATE233084T1
Authority: AT; Austria
Prior art keywords: pharmaceutical aerosol; formulations; aerosol formulation; relates; novel
Prior art date: 1999-04-14

Application number

AT00925450T

Other languages

English (en)

Inventor

Cecile Isabelle Bonvoisin

Christophe Laroche

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-14

Filing date

2000-04-13

Publication date

2003-03-15

1999-09-10 Priority claimed from GBGB9921289.6A external-priority patent/GB9921289D0/en

2000-04-13 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2003-03-15 Application granted granted Critical

2003-03-15 Publication of ATE233084T1 publication Critical patent/ATE233084T1/de

Links

239000000203 mixture Substances 0.000 title abstract 5
238000009472 formulation Methods 0.000 title abstract 4
239000008249 pharmaceutical aerosol Substances 0.000 title abstract 2
239000002245 particle Substances 0.000 abstract 2
YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 abstract 1
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 abstract 1
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 abstract 1
239000011248 coating agent Substances 0.000 abstract 1
238000000576 coating method Methods 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
239000003380 propellant Substances 0.000 abstract 1
230000002685 pulmonary effect Effects 0.000 abstract 1
229960005018 salmeterol xinafoate Drugs 0.000 abstract 1
238000001694 spray drying Methods 0.000 abstract 1
239000004094 surface-active agent Substances 0.000 abstract 1
239000000725 suspension Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Otolaryngology (AREA)
Pulmonology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT00925450T 1999-04-14 2000-04-13 Pharmazeutische aerosolformulierung ATE233084T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
BH12699		1999-04-14
GBGB9921289.6A GB9921289D0 (en)	1999-09-10	1999-09-10	Pharmaceutical aerosol formulation
PCT/GB2000/001418 WO2000061108A1 (en)	1999-04-14	2000-04-13	Pharmaceutical aerosol formulation

Publications (1)

Publication Number	Publication Date
ATE233084T1 true ATE233084T1 (de)	2003-03-15

Family

ID=25663377

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00925450T ATE233084T1 (de)	1999-04-14	2000-04-13	Pharmazeutische aerosolformulierung

Country Status (10)

Country	Link
US (1)	US7090831B1 (de)
EP (1)	EP1169019B1 (de)
JP (1)	JP2002541183A (de)
AT (1)	ATE233084T1 (de)
AU (1)	AU4417500A (de)
DE (1)	DE60001492T2 (de)
DK (1)	DK1169019T3 (de)
ES (1)	ES2193069T3 (de)
PT (1)	PT1169019E (de)
WO (1)	WO2000061108A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080064613A1 (en) *	2006-09-11	2008-03-13	M-I Llc	Dispersant coated weighting agents
DE60140268D1 (de) *	2000-11-30	2009-12-03	Vectura Ltd	Partikel zur verwendung in einer pharmazeutischen zusammensetzung
ES2474199T3 (es)	2000-11-30	2014-07-08	Vectura Limited	Composiciones farmacéuticas para inhalaci�n
CZ305498B6 (cs) *	2000-12-22	2015-11-04	Glaxo Group Limited	Kontejner a balení zahrnující inhalátor odměřených dávek
JP2005504076A (ja) *	2001-09-14	2005-02-10	ベーリンガーインゲルハイムファルマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフト	新規な吸入用医薬組成物
WO2004016247A1 (en) *	2002-08-14	2004-02-26	E.I. Du Pont De Nemours And Company	Process for coating a pharmaceutical particle
PE20040950A1 (es)	2003-02-14	2005-01-01	Theravance Inc	DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CA2524538A1 (en) *	2003-05-19	2004-12-02	Baxter International Inc.	Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
GB0321607D0 (en)	2003-09-15	2003-10-15	Vectura Ltd	Manufacture of pharmaceutical compositions
CN1878602A (zh) *	2003-11-28	2006-12-13	三菱化学株式会社	有机化合物微粒的制造方法
TWI341836B (en)	2004-03-11	2011-05-11	Theravance Inc	Biphenyl compounds useful as muscarinic receptor antagonists
WO2006023460A2 (en)	2004-08-16	2006-03-02	Theravance, Inc.	COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
JPWO2009069619A1 (ja) *	2007-11-27	2011-04-14	株式会社Ｅｒｃテクノロジー	オゾン化界面活性剤を含有する新規組成物
EP2393488B1 (de)	2009-02-06	2019-06-19	University Of Southern California	Therapeutische zusammensetzungen mit monoterpenen
US8815258B2 (en)	2009-05-29	2014-08-26	Pearl Therapeutics, Inc.	Compositions, methods and systems for respiratory delivery of two or more active agents
PL3111927T3 (pl)	2009-05-29	2020-06-29	Pearl Therapeutics, Inc.	Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy
KR101742252B1 (ko)	2009-07-15	2017-05-31	세라밴스 바이오파마 알앤디 아이피, 엘엘씨	비페닐 화합물의 결정질 유리 염기형
US8507734B2 (en)	2010-03-03	2013-08-13	Neonc Technologies Inc.	Pharmaceutical compositions comprising monoterpenes
EP3173080B1 (de)	2010-08-27	2019-12-11	Neonc Technologies Inc.	Pharmazeutische zusammensetzungen mit derivaten des perillaalkohols
US20160038600A1 (en)	2012-08-03	2016-02-11	Neonc Technologies Inc.	Pharmaceutical compositions comprising poh derivatives
CN105616391B (zh)	2010-12-17	2021-03-19	尼昂克技术公司	使用异紫苏醇的方法和装置
TWI597072B (zh)	2011-10-11	2017-09-01	吉斯藥品公司	包覆脂肪酸的β－致效劑之結晶微粒
EP2968312B1 (de)	2013-03-15	2018-01-31	Verona Pharma PLC	Arzneimittelkombination
SG11201507286QA (en)	2013-03-15	2015-10-29	Pearl Therapeutics Inc	Methods and systems for conditioning of particulate crystalline materials
DE102013021718B4 (de) *	2013-12-20	2017-03-02	Gerresheimer Regensburg Gmbh	Kapsel zur Verwendung als Reservoir für eine pharmazeutische, vorzugsweise pulverförmige Zubereitung in einem Inhalator sowie Inhalator dafür
PL3231444T3 (pl)	2014-05-12	2020-05-18	Verona Pharma Plc	Nowe leczenie
KR20170131405A (ko)	2015-02-12	2017-11-29	네온씨 테크놀로지스, 아이엔씨.	페릴릴 알코올 유도체를 포함하는 의약 조성물
DK3547836T3 (da)	2016-11-30	2024-11-18	Univ Southern California	Perillylalkohol-3 brompyruvat-konjugat og fremgangsmåder til behandling af cancer
DK3749291T3 (da)	2018-02-08	2024-04-08	Univ Southern California	Fremgangsmåder til permeabilisering af blod-hjerne-barrieren
US12329727B2 (en)	2020-04-24	2025-06-17	The Medical College Of Wisconsin, Inc.	Use of salmeterol as an anti-coronaviral agent

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1535531A (en) *	1976-10-15	1978-12-13	Warmer & Co Ltd W	Pharmaceutical compositions
ZW6584A1 (en)	1983-04-18	1985-04-17	Glaxo Group Ltd	Phenethanolamine derivatives
NZ221411A (en)	1986-08-11	1989-10-27	Innovata Biomed Ltd	Pharmaceutical compositions containing microcapsules and a surfactant
GB8921222D0 (en)	1989-09-20	1989-11-08	Riker Laboratories Inc	Medicinal aerosol formulations
CA2081474A1 (en)	1990-05-08	1991-11-09	Manzer Durrani	Direct spray-dried drug/lipid powder composition
GB9024366D0 (en)	1990-11-09	1991-01-02	Glaxo Group Ltd	Medicaments
GB9024365D0 (en)	1990-11-09	1991-01-02	Glaxo Group Ltd	Medicaments
GB9026005D0 (en)	1990-11-29	1991-01-16	Glaxo Group Ltd	Drug material suitable for micronisation
IL104068A (en)	1991-12-12	1998-10-30	Glaxo Group Ltd	Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
CA2455115C (en)	1991-12-12	2008-05-27	Glaxo Group Limited	Pharmaceutical aerosol formulation
DK0550031T3 (da)	1991-12-31	1996-08-26	Solvay	Medicinsk aerosolformulering
MX9304585A (es)	1992-07-31	1994-03-31	Glaxo Group Ltd	Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
EP0655237A1 (de)	1993-11-27	1995-05-31	Hoechst Aktiengesellschaft	Medizinische Aerosolformulierung
GB9419536D0 (en) *	1994-09-28	1994-11-16	Glaxo Inc	Medicaments
JPH08151322A (ja) *	1994-09-30	1996-06-11	Takeda Chem Ind Ltd	経口徐放剤
GB9425160D0 (en) *	1994-12-10	1995-02-08	Glaxo Group Ltd	Medicaments
GB9606188D0 (en)	1996-03-23	1996-05-29	Danbiosyst Uk	Pollysaccharide microspheres for the pulmonary delivery of drugs
AU5719798A (en)	1996-12-31	1998-07-31	Inhale Therapeutic Systems, Inc.	Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
ATE228823T1 (de)	1998-04-18	2002-12-15	Glaxo Group Ltd	Pharmazeutische aerosolformulierung
GB9828721D0 (en)	1998-12-24	1999-02-17	Glaxo Group Ltd	Novel apparatus and process

2000
- 2000-04-13 DK DK00925450T patent/DK1169019T3/da active
- 2000-04-13 AU AU44175/00A patent/AU4417500A/en not_active Abandoned
- 2000-04-13 JP JP2000610441A patent/JP2002541183A/ja active Pending
- 2000-04-13 EP EP00925450A patent/EP1169019B1/de not_active Expired - Lifetime
- 2000-04-13 US US09/958,788 patent/US7090831B1/en not_active Expired - Fee Related
- 2000-04-13 AT AT00925450T patent/ATE233084T1/de not_active IP Right Cessation
- 2000-04-13 WO PCT/GB2000/001418 patent/WO2000061108A1/en not_active Ceased
- 2000-04-13 PT PT00925450T patent/PT1169019E/pt unknown
- 2000-04-13 ES ES00925450T patent/ES2193069T3/es not_active Expired - Lifetime
- 2000-04-13 DE DE60001492T patent/DE60001492T2/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2193069T3 (es)	2003-11-01
DE60001492T2 (de)	2003-12-18
WO2000061108A1 (en)	2000-10-19
US7090831B1 (en)	2006-08-15
JP2002541183A (ja)	2002-12-03
AU4417500A (en)	2000-11-14
DE60001492D1 (de)	2003-04-03
DK1169019T3 (da)	2003-06-02
EP1169019B1 (de)	2003-02-26
PT1169019E (pt)	2003-07-31
EP1169019A1 (de)	2002-01-09

Legal Events

Date

Code

Title

Description

2003-08-15

UEP

Publication of translation of european patent specification

Ref document number: 1169019

Country of ref document: EP

2010-01-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE233084T1 (de)	2003-03-15	Pharmazeutische aerosolformulierung
AP2000001961A0 (en)	2000-12-31	Pharmaceutical aerosol formulation.
DE60123793D1 (de)	2006-11-23	Neue aerosolformulierungen ein polares fluoriniertes molekül enthaltend
ES2178817T3 (es)	2003-01-01	Formulaciones medicinales de aerosol.
NO20010391D0 (no)	2001-01-23	Medisinske aerosolformuleringer
ATE216575T1 (de)	2002-05-15	Treibgasmischung für eine aerosolzubereitung
DE60019167D1 (de)	2005-05-04	Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
ATE398999T1 (de)	2008-07-15	Aerosol-formulierungen von formoterol und mometason
ES2064160T3 (es)	1995-01-16	Formulacion de aerosol que comprende 17,21-dipropionato de beclometasona.
HUP0002691A2 (hu)	2001-02-28	Ciklezonid tartalmú gyógyászati aeroszol termékek
CA2441549A1 (en)	2002-10-31	Ipratropium formulation for pulmonary inhalation
WO1999024016A8 (en)	1999-07-29	Emulsions for aerosolization and drug delivery
EP1523976A3 (de)	2005-06-22	Pharmazeutische Formulierungen enthaltend Salmeterol
BR0303347A (pt)	2004-07-13	Formulações de aerossol contendo ésteres de derivados de 3,17-diidroxi estratieno para deposição pulmonar
TH29519B (th)	1998-08-14	สูตรผสมทางเภสัชศาสตร์ที่เสถียรชนิดใหม่สำหรับการผลิตละอองลอยที่ไม่มีแก๊สผลักดัน